Outlook Therapeutics
OTLK
54 hedge funds and large institutions have $2.21M invested in Outlook Therapeutics in 2026 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 15 increasing their positions, 6 reducing their positions, and 14 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 6
139% more call options, than puts
Call options by funds: $79K | Put options by funds: $33K
14% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 14
2.04% more ownership
Funds ownership: 10.64% → 12.68% (+2%)
2% more funds holding
Funds holding: 53 → 54 (+1)
80% less capital invested
Capital invested by funds: $10.8M → $2.21M (-$8.57M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$1.8M |
| 2 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$154K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$124K |
| 4 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
+$119K |
| 5 |
Renaissance Technologies
New York
|
+$110K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSA
Schonfeld Strategic Advisors
New York
|
-$3.86M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$472K |
| 3 |
Millennium Management
New York
|
-$260K |
| 4 |
SC
Scotia Capital
Toronto,
Ontario, Canada
|
-$117K |
| 5 |
LA
LVW Advisors
Pittsford,
New York
|
-$76.2K |
OTLK Hedge Fund Activity: Q1 2026 in Review
54 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q1 2026, worth a combined $2.21M — down 80% from $10.8M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new OTLK positions and 14 closed out — a net gain of 2 holders — while 15 added to existing stakes and 6 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $1.8M. The largest seller was Schonfeld Strategic Advisors, exiting entirely with an estimated $3.86M sold.
- 54 institutional investors held Outlook Therapeutics (OTLK) as of Q1 2026, up from 53 in Q4 2025.
- Funds reported $2.21M of Outlook Therapeutics stock for Q1 2026, down 80% quarter-over-quarter.
- 16 funds opened new Outlook Therapeutics positions in Q1 2026 and 14 closed out, a net change of +2 holders.
- The largest Outlook Therapeutics buyer in Q1 2026 was Armistice Capital, an estimated $1.8M added.
- The largest Outlook Therapeutics seller in Q1 2026 was Schonfeld Strategic Advisors, an estimated $3.86M sold.
Based on aggregated 13F filings for Q1 2026.